The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Jul. 11, 2019
Applicant:

Yeda Research and Development Co. Ltd., Rehovot, IL;

Inventors:

Yair Reisner, Houston, TX (US);

Esther Bachar-Lustig, Rehovot, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61K 35/17 (2015.01); A61K 35/22 (2015.01); A61K 35/38 (2015.01); A61K 35/39 (2015.01); A61K 35/407 (2015.01); A61K 35/42 (2015.01); A61K 31/675 (2006.01); A61K 35/34 (2015.01); A61K 35/36 (2015.01); C12N 5/00 (2006.01); A61K 31/198 (2006.01); A61K 31/255 (2006.01); A61K 31/7076 (2006.01); A61P 37/06 (2006.01); A61P 37/02 (2006.01); A61K 31/661 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 31/198 (2013.01); A61K 31/255 (2013.01); A61K 31/661 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 35/22 (2013.01); A61K 35/34 (2013.01); A61K 35/36 (2013.01); A61K 35/38 (2013.01); A61K 35/39 (2013.01); A61K 35/407 (2013.01); A61K 35/42 (2013.01); A61K 39/3955 (2013.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); C12N 5/0087 (2013.01); A61K 2035/124 (2013.01); A61K 2039/507 (2013.01); A61K 2039/515 (2013.01); C12N 2501/06 (2013.01);
Abstract

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10CD3T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×10CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.


Find Patent Forward Citations

Loading…